214 related articles for article (PubMed ID: 29590326)
21. Immunogenicity and safety of a live herpes zoster vaccine in hematopoietic stem cell transplant recipients.
Chun JY; Kim K; Lee MK; Kang CK; Koh Y; Shin DY; Hong J; Choe PG; Kim NJ; Yoon SS; Park WB; Kim I; Oh MD
BMC Infect Dis; 2021 Jan; 21(1):117. PubMed ID: 33499826
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of Varicella-zoster virus-specific cell-mediated immunity by interferon-γ Enzyme-Linked Immunosorbent Assay in adults ≥50 years of age administered a herpes zoster vaccine.
Yang P; Chen Z; Zhang J; Li W; Zhu C; Qiu P; Quan Y; Cui X; Yuan L; Jiang C
J Med Virol; 2019 May; 91(5):829-835. PubMed ID: 30613990
[TBL] [Abstract][Full Text] [Related]
23. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: a randomised non-inferiority clinical trial.
Diez-Domingo J; Weinke T; Garcia de Lomas J; Meyer CU; Bertrand I; Eymin C; Thomas S; Sadorge C
Vaccine; 2015 Feb; 33(6):789-95. PubMed ID: 25555381
[TBL] [Abstract][Full Text] [Related]
24. Varicella-zoster virus-specific cell-mediated immune responses in HIV-infected adults.
De Castro N; Carmagnat M; Kernéis S; Scieux C; Rabian C; Molina JM
AIDS Res Hum Retroviruses; 2011 Oct; 27(10):1089-97. PubMed ID: 21417759
[TBL] [Abstract][Full Text] [Related]
25. The Safety and Immunologic Effectiveness of the Live Varicella-Zoster Vaccine in Patients Receiving Tumor Necrosis Factor Inhibitor Therapy : A Randomized Controlled Trial.
Curtis JR; Cofield SS; Bridges SL; Bassler J; Deodhar A; Ford TL; Huffstutter J; Jankeel A; Kivitz A; Kamal S; Lindsey S; Messaoudi I; Mendoza N; Michaud K; Mikuls TR; Ridley D; Shergy W; Siegel SAR; Winthrop KL
Ann Intern Med; 2021 Nov; 174(11):1510-1518. PubMed ID: 34570596
[TBL] [Abstract][Full Text] [Related]
26. Vaccines for preventing herpes zoster in older adults.
Gagliardi AM; Andriolo BN; Torloni MR; Soares BG; de Oliveira Gomes J; Andriolo RB; Canteiro Cruz E
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31696946
[TBL] [Abstract][Full Text] [Related]
27. Safety and immunogenicity of a live attenuated varicella vaccine in VZV-seropositive HIV-infected adults.
Weinberg A; Levin MJ; Macgregor RR
Hum Vaccin; 2010 Apr; 6(4):318-21. PubMed ID: 20372089
[TBL] [Abstract][Full Text] [Related]
28. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4(+) T cells.
Levin MJ; Gershon AA; Weinberg A; Song LY; Fentin T; Nowak B;
J Infect Dis; 2006 Jul; 194(2):247-55. PubMed ID: 16779732
[TBL] [Abstract][Full Text] [Related]
29. Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve.
Gilbert PB; Gabriel EE; Miao X; Li X; Su SC; Parrino J; Chan IS
J Infect Dis; 2014 Nov; 210(10):1573-81. PubMed ID: 24823623
[TBL] [Abstract][Full Text] [Related]
30. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study.
Lal H; Poder A; Campora L; Geeraerts B; Oostvogels L; Vanden Abeele C; Heineman TC
Vaccine; 2018 Jan; 36(1):148-154. PubMed ID: 29174683
[TBL] [Abstract][Full Text] [Related]
31. Safety and immune response of a live-attenuated herpes zoster vaccine in patients with systemic lupus erythematosus: a randomised placebo-controlled trial.
Mok CC; Chan KH; Ho LY; Fung YF; Fung WF; Woo PCY
Ann Rheum Dis; 2019 Dec; 78(12):1663-1668. PubMed ID: 31530556
[TBL] [Abstract][Full Text] [Related]
32. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine.
Weinberg A; Zhang JH; Oxman MN; Johnson GR; Hayward AR; Caulfield MJ; Irwin MR; Clair J; Smith JG; Stanley H; Marchese RD; Harbecke R; Williams HM; Chan IS; Arbeit RD; Gershon AA; Schödel F; Morrison VA; Kauffman CA; Straus SE; Schmader KE; Davis LE; Levin MJ;
J Infect Dis; 2009 Oct; 200(7):1068-77. PubMed ID: 19712037
[TBL] [Abstract][Full Text] [Related]
33. Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.
Grupping K; Campora L; Douha M; Heineman TC; Klein NP; Lal H; Peterson J; Vastiau I; Oostvogels L
J Infect Dis; 2017 Dec; 216(11):1343-1351. PubMed ID: 29029122
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial.
Pollard RB; Rockstroh JK; Pantaleo G; Asmuth DM; Peters B; Lazzarin A; Garcia F; Ellefsen K; Podzamczer D; van Lunzen J; Arastéh K; Schürmann D; Clotet B; Hardy WD; Mitsuyasu R; Moyle G; Plettenberg A; Fisher M; Fätkenheuer G; Fischl M; Taiwo B; Baksaas I; Jolliffe D; Persson S; Jelmert O; Hovden AO; Sommerfelt MA; Wendel-Hansen V; Sørensen B
Lancet Infect Dis; 2014 Apr; 14(4):291-300. PubMed ID: 24525316
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity and Safety of a Live Attenuated Zoster Vaccine (ZOSTAVAX™) in Korean Adults.
Choi WS; Choi JH; Choi JY; Eom JS; Kim SI; Pai H; Peck KR; Sohn JW; Cheong HJ
J Korean Med Sci; 2016 Jan; 31(1):13-7. PubMed ID: 26770032
[TBL] [Abstract][Full Text] [Related]
36. Association between quantitative varicella-zoster virus antibody levels and zoster reactivation in HIV-infected persons.
Pomerantz HS; Xu X; White J; Sunil TS; Deiss RG; Ganesan A; Agan BK; Okulicz JF
AIDS Res Ther; 2018 Dec; 15(1):25. PubMed ID: 30537970
[TBL] [Abstract][Full Text] [Related]
37. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial.
Ndiaye BP; Thienemann F; Ota M; Landry BS; Camara M; Dièye S; Dieye TN; Esmail H; Goliath R; Huygen K; January V; Ndiaye I; Oni T; Raine M; Romano M; Satti I; Sutton S; Thiam A; Wilkinson KA; Mboup S; Wilkinson RJ; McShane H;
Lancet Respir Med; 2015 Mar; 3(3):190-200. PubMed ID: 25726088
[TBL] [Abstract][Full Text] [Related]
38. Protocol of a randomised controlled trial characterising the immune responses induced by varicella-zoster virus (VZV) vaccination in healthy Kenyan women: setting the stage for a potential VZV-based HIV vaccine.
Perciani CT; Jaoko W; Walmsley S; Farah B; Mahmud SM; Ostrowski M; Anzala O; Team KI; MacDonald KS
BMJ Open; 2017 Sep; 7(9):e017391. PubMed ID: 28939581
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity and safety of a live-attenuated varicella vaccine in a healthy population aged 13 years and older: A randomized, double-blind, controlled study.
Huang L; Chen Z; Song Y; Tan J; Jia N; You W; Yuan H; Feng G; Li C; Luan C; Quan Y; Wang Y
Vaccine; 2024 Jan; 42(2):396-401. PubMed ID: 38057208
[TBL] [Abstract][Full Text] [Related]
40. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax.
Gilderman LI; Lawless JF; Nolen TM; Sterling T; Rutledge RZ; Fernsler DA; Azrolan N; Sutradhar SC; Wang WW; Chan IS; Schlienger K; Schödel F; Silber JL;
Clin Vaccine Immunol; 2008 Feb; 15(2):314-9. PubMed ID: 18077611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
